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DIGETreatment options for toxoplasmosis in humans are generally limited to the use of sulfonamide and/or
pyrimethamine-based compounds. However, there is increasing evidence for clinical therapy failures
in patients suggesting the existence of drug resistance in these classes of drug. In vitro resistance to sul-
fadiazine has been detected in three strains of Toxoplasma gondii isolated from clinical cases. In order to
begin to understand the mechanisms of resistance, we undertook a difference-gel electrophoresis (DIGE)
approach combined with mass spectrometry to identify proteins that are differentially expressed in sul-
fadiazine-resistance strains of the parasite. Naturally resistant strains TgA 103001 (Type I), TgH 32006
(Type II) and TgH 32045 (Type II variant) were compared to sensitive strains RH (Type I) and ME-49 (Type
II) using DIGE and the modulated proteins analyzed using LC–MS/MS. In total, 68 differentially expressed
protein spots were analyzed by mass spectrometer and 31 unique proteins, including four hypothetical
proteins, were identiﬁed. Among the differentially expressed proteins, 44% were over-expressed in resis-
tant strains and 56% were over-expressed in sensitive strains. The virulence-associated rhoptry protein,
ROP2A, was found in greater abundance in both naturally resistant Type II strains TgH 32006 and TgH
32045 compared to the sensitive strain ME-49. Enolase 2 and IMC1 were found to be in greater abun-
dance in sensitive strains RH and ME-49, and MIC2 was found to be more abundant in the sensitive strain
ME-49. Proteins regulation of ROP2, MIC2, ENO2, IMC1 and GRA7 were conﬁrmed by Western blot anal-
ysis. In addition, gene expression patterns of ROP2, MIC2, ENO2 and IMC1 were analyzed with qRT-PCR.
This study provides the ﬁrst proteomics insights into sulfadiazine resistance in T. gondii resistant strains
isolated from clinical cases.
 2013 Australian Society for Parasitology. Published by Elsevier Ltd. All rights reserved.1. Introduction
Toxoplasma gondii, the causative agent of toxoplasmosis, is an
obligate intracellular protozoan parasite that infects more than
one-third of the world’s human population. The population struc-
ture of T. gondii consists of three main clonal lineages (Types I, II
and III) correlated with virulence expression in mice. Recently, a
study reveal a biphasic pattern consisting of regions in the North-
ern Hemisphere where a few, highly clonal and abundant lineages
predominate; elsewhere, and especially in portions of South Amer-
ica are characterized by a diverse assemblage of less common
genotypes that show greater evidence of recombination (Su et al.,
2012).
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cause severe clinical diseases such as encephalitis or systemic
infection in immuno-compromised patients, particularly individu-
als with HIV infection and in cases of congenital toxoplasmosis
(Weiss and Dubey, 2009). This disease can be fatal if untreated in
immuno-compromised patients and current therapeutic options
for the treatment of toxoplasmosis are limited to combinations of
sulfonamides and pyrimethamine. In congenital infection, treat-
ment with this combination could improve prognosis of illness
(McLeod et al., 2006). These drugs have a synergistic action on
T. gondii folate synthesis by inhibiting two major enzymes: dihy-
dropteroate synthase (DHPS) and dihydrofolate reductase (DHFR)
which are essential for parasite survival and replication. Neverthe-
less several treatment failures have been reported for the treat-
ment of toxoplasmic encephalitis, chorioretinitis, and congenital
toxoplasmosis (Dannemann et al., 1992; Katlama et al., 1996;
Torres et al., 1997; Baatz et al., 2006; Petersen, 2007). Several
pharmacological parameters may contribute to these failures:
malabsorption, drug intolerance, compliance or tissue diffusion.
However, given the target of drugs used in the treatment of
toxoplasmosis, the existence of factors of resistance or lower sus-
ceptibility depending on the parasite strain may be suspected.
Recently, Meneceur et al. (2008) evaluated the sulfadiazine sus-
ceptibilities of 17 T. gondii strains in vitro by calculating IC50
according to a method developed by Derouin and Chastang
(1988). At the present time only three strains (TgA 103001 previ-
ously described as B1 (Type I strain), TgH 32006 previously de-
scribed as RMS-1995-ABE (Type II strain) and TgH 32045
previously described as RMS-2001-MAU (Type II variant strain))
are resistant to sulfadiazine, as deﬁned by an IC50 value for sulfadi-
azine >50 mg/l on MRC5 cells in comparison with the other strains
studied which had IC50 ranging from 3 to 18.8 mg/l. No apparent
correlation with strain genotype or to mutations in known drug
target genes were found for these three strains (Meneceur et al.,
2008). Thus, the mechanism of resistance to sulfadiazine in
T. gondii remains unclear.
The use of proteomic techniques offers an excellent platform to
investigate aspects of numerous biological processes, like acquired
drug resistance. Thus, proteomics approaches have been demon-
strated as a very powerful tool in investigating drug resistance
mechanisms in several parasites, such as Trypanosoma cruzi
(Andrade et al., 2008) and Leishmania spp. (Kumar et al., 2010). In
the T. cruzi study, two-dimensional gel electrophoresis (2-DE) was
used to analyze the differentially expressed proteins of T. cruziwith
selected in vivo and in vitro resistance to benznidazole and their sus-
ceptible clones: the identiﬁcation of 56 proteins among which 27
novel proteins were identiﬁed as over-expressed in the resistant
phenotype, have provided valuable information for the investiga-
tion of the resistance mechanisms in T. cruzi (Andrade et al., 2008).
By using 2-DE, Kumar et al. (2010) compared the proteome proﬁle
of membrane-enriched, as well as cytosolic proteins of resistant
and sensitive Indian Leishmania donovani: 20 differentially ex-
pressed proteins were identiﬁed, including ABC transporters and
Hsp83alreadyknowntobe implicated in the resistancemechanisms
of L. donovani (Vergnes et al., 2007; Castanys-Munoz et al., 2008).
Moreover, several proteomics studies have been performed on
T. gondii, for example Xia et al. (2008) characterized the proteome
of T. gondii tachyzoites and identiﬁed nearly one-third of the entire
proteome. Nelson et al. (2008) employed a quantitative proteomic
approach to investigate the modulation of host cells by T. gondii
invasion; they provided evidence for global reprogramming of cell
metabolism and demonstrated the intimate relationship between
pathogen and host. However, none of the proteomic studies have
investigated the resistance mechanisms of T. gondii to sulfadiazine.
The present study aimed to investigate differentially expressed
proteins in natural sulfadiazine resistant and sensitive strains ofT. gondii by using difference-gel electrophoresis (DIGE). Proteins
regulation of several proteins identiﬁed in DIGE were conﬁrmed
by Western blotting. In addition, qRT-PCR was performed on
some proteins identiﬁed as differentially regulated to
complement results obtained from the proteomic analyses. The
identiﬁcation of proteins that are associated with sulfadiazine
resistance will improve our understanding of the resistance
mechanisms and enhance the development of new treatments of
toxoplasmosis.2. Materials and methods
2.1. Toxoplasma gondii strains
Seven strains of T. gondii tachyzoites were used in this study:
RH and ENT (Type I, sensitive strain), TgA 103001 (Type I, resistant
strain), ME-49 and PRU (Type II, sensitive strain), TgH 32006 (Type
II, resistant strain) and TgH 32045 (deﬁned as Type II variant,
resistant strain). Indeed, this strain was phylogenetically included
in the Type II cluster because of its Type II genetic background, as
described by Ajzenberg et al. (2004). All strains studied were
provided by the French Biological Resource Center Toxoplasma
(BRC Toxoplasma, France) and are previously described (Meneceur
et al., 2008). All BRC Toxoplasma strains were genotyped by using a
multiplex PCR designed for multiloci strains typing with 15
microsatellites markers (Ajzenberg et al., 2010).2.2. Cell culture
T. gondii tachyzoites were maintained on African green monkey
kidney (Vero) cell monolayers (ATCC, CCL-81) at 37 C in a 5% CO2
humidiﬁed incubator. Cells and parasites were grown in Iscove’s
Modiﬁed Dulbecco’s Medium (Invitrogen) supplemented with 2%
(v/v) fetal calf serum (Biowest), 1% (v/v) L-glutamine (GIBCO),
and antibiotics (100 IU/mL penicillin and 0.1 mg/mL streptomycin)
(GIBCO). The parasites were routinely checked forMycoplasma spp.
contamination and found to be negative using a Mycoplasma spp.
real-time PCR (Ishikawa et al., 2006). Parasite growth rates varied
depending on strain genotypes (Meneceur et al., 2008); host cells
were infected at different parasite to cell ratio to synchronize
parasite culture and to obtain extracellular parasites in 4 days for
all strains studied (multiplicity of infection used in the study was
(parasite:cell): 1:1 for the Type I strains, 4:1 for the Type II strains
and 6:1 for the Type II variant strain). After 24 h, cells and parasites
were washed once in PBS 1 (pH 7.4) to eliminate extracellular
parasites. Then the intracellular multiplication of tachyzoites was
observed (8–32 tachyzoites per rosace) until the fourth day
post-infection when tachyzoites were harvested from culture and
the Toxoplasma stage preparation was veriﬁed by qRT-PCR by using
tachyzoites markers and bradyzoites markers (Supplemental data
1). Parasites used in this study were cultivated from passages
3–9 on Vero cells. For 2D-DIGE analysis, four samples of parasites
came from the same cell culture passage. For qRT-PCR analysis,
we used six samples: one sample came from the same passage as
in 2D-DIGE and the ﬁve other samples came from additional
passages. Then, parasites were separated from host cells by
ﬁltration through 3 lm polycarbonate ﬁlters (Whatman Interna-
tional). Tachyzoites were washed twice with PBS (pH 7.4) with
centrifugation at 1500g for 20 min at 4 C. For protein analysis,
parasites were then counted, pelleted and stored at 80 C in
batches of at least of 2  108 parasites. For each strain studied, four
biological replicates were used: parasites derived from four
separate ﬂasks of the same strain. For gene expression analysis,
parasites were counted and total RNA was extracted as described
in Section 2.10.
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Frozen tachyzoite pellets were solubilized in lysis buffer (8 M
urea, 4% (w/v) CHAPS, 40 mM Tris base) containing DNase/RNase
and protease inhibitors (Roche); and subjected to three rapid
(2 min) cycles of freezing in liquid nitrogen/defrosting at 30 C
with vigorous vortexing. Samples were centrifuged at 13,000g for
30 min at 4 C. Samples were then precipitated with the 2D-Clean
up Kit (GE Healthcare), resuspended in 50 lL of sample buffer (8 M
urea, 2% (w/v) CHAPS) and the concentration was determined
using Protein assay kit (BioRad). Protein samples were minimally
labeled with CyDye according to the manufacturer’s protocols
(GE Healthcare). Brieﬂy, 50 lg of sample was labeled with
400 pmol of Cy3 or Cy5 ﬂuorochromes dissolved in DMF for
30 min at 4 C in the dark. Labeling reactions were quenched by
the addition of 10 mM lysine for 10 min at 4 C in the dark. Four
different aliquots of sensitive strains and four different aliquots
of resistant strains were compared for each experiment. An inter-
nal standard was prepared by pooling equal amounts of protein
from each biological sample in the experiment. This was labeled
with Cy2 dye and then was included in all the gels.
2.4. DIGE
The DIGE workﬂow consisted in four analyzed gels, each con-
taining one aliquot of sensitive and one aliquot of resistant strains,
and one preparative gel used to pick the interest spots. A total of
150 lg of protein per gel containing the internal standard (Cy2-la-
beled), sensitive strain tachyzoites (Cy3-labeled for gels 1 and 2,
Cy5-labeled for gels 3 and 4) and resistant strain tachyzoites
(Cy5-labeled for gels 1 and 2, Cy3-labeled for gels 3 and 4) were
mixed together and separated on the four 2D-gels. One gel includ-
ing 300 lg of standard protein sample was used as preparative gel.
The 24 cm nonlinear, pH 3–10, IPG strips (GE Healthcare) were
rehydrated with 0.45 mL rehydration buffer (8 M urea, 2% (w/v)
CHAPS w/v, 18 mM DTT and 2% (v/v) IPG buffer, pH 3–10) contain-
ing the 150 lg of protein. IEF was performed with an IPGphor II
unit (GE Healthcare) up to a total of 65 kVh according to manufac-
turer’s instructions. Before the second dimension, strips were
equilibrated twice in 10 mL equilibration buffer (6 M urea, 30%
(v/v) glycerol, 2% (v/v) SDS, 75 mM Tris–HCl, pH 8.8), ﬁrst for
15 min adding 1% (w/v) DTT and secondly for 15 min by adding
2.5% (w/v) iodoacetamide. Strips were sealed with 0.5% (w/v) aga-
rose to 12.5% (v/v) polyacrylamide gels and proteins were sepa-
rated in 1 running buffer (25 mM Tris-base, 192 mM Glycine,
0.2% (w/v) SDS) in the bottom chamber and 2 running buffer in
the top chamber at 5 W/gel for 0.5 h and 17W/gel thereafter in
an Ettan Dalt Six unit (GE Healthcare).
2.5. Sypro Ruby staining
Total proteins on the preparative gel were visualized by staining
with Sypro Ruby protein gel stain (Molecular Probes). The gel was
ﬁxed in 40% (v/v) methanol, 10% (v/v) acetic acid overnight at then
stained in Sypro Ruby. Before scanning, the gel was washed for 1 h
in 10% (v/v) methanol and 7% (v/v) acetic acid and rinsed twice in
distilled water for 5 min.
2.6. Image analysis and statistics
Proteins were visualized using Ettan DIGE Imager 1.0 (GE
Healthcare) with CyDye ﬁlters. For the Cy2, Cy3 and Cy5 ﬂuoro-
chromes, the excitation wavelengths were respectively 480/30,
540/25 and 633/30 nm and emission wavelengths were 530/40,
595/25 and 680/30 nm. All gels were scanned at 100 lm resolu-
tion. Image analysis was carried out with DeCyder 2D software ver-sion 6.5 (GE Healthcare). The DIA (differential in-gel analysis
module) was used to co-detect, normalize with the internal stan-
dard from each 2D-gels and differentially quantitate the protein
spots in the image. The matching of the different maps from each
gel and the statistical analysis of protein variation between sam-
ples (resistant/sensitive) was performed by the BVA (Biological
Variation Analysis Module) (Alban et al., 2003; Marouga et al.,
2005). Protein spots which appeared in at least 9 out of 12 images
with greater than 1.3-fold changes (p 6 0.05, Student’s t-test) were
considered as differentially expressed between strains.2.7. In-gel tryptic digestion
Protein spots of interest were excised from the gel and gel plugs
were incubated twice at 37 C for 10 min in 50 mM ammonium
bicarbonate/50% acetonitrile. Gel plugs were then dehydrated with
100% (v/v) acetonitrile at 37 C for 15 min and rehydrated with
10 lL of 10 ng/lL sequencing grade trypsin in 25 mM ammonium
bicarbonate at 37 C for 1 h. Then, 25 mM ammonium bicarbonate
was added to cover the gel pieces, which were left at 37 C over-
night. The reaction was stopped with 2 lL of 2.6 M formic acid
and the samples were stored at 20 C (Xia et al., 2008).2.8. MS analysis (LC–MS/MS)
Mass spectrometry analyses were performed using an LTQ ion-
trap mass spectrometer (Thermo Electron) coupled on-line to a
Dionex Ultimate 3000 (Dionex) HPLC system equipped with a nano
pepMap100 C18 reversed phase column (75 lm; 3 lm, 100 Å).
Water and solvents were all HPLC grade. The column was equili-
brated in 97.9% (v/v) water/2% (v/v) acetonitrile/0.1% (v/v) formic
acid (FA) at a ﬂow rate of 300 nL/min. Sample injections of 15 lL
of tryptic peptides were loaded onto a C18 TRAP, desalted and
washed for 3 min at a ﬂow rate of 25 lL/min prior to being loaded
onto a nano pepMap100 C18 column at 300 nL/min. The peptides
were eluted at a ﬂow rate of 300 nL/min with a linear gradient of
0–50% (v/v) acetonitrile/0.1% (v/v) FA over 30 min, followed by
80% (v/v) acetonitrile/0.1% (v/v) FA for 5 min. The column was then
equilibrated in 97.9% water/2% acetonitrile/0.1% (v/v) FA for 5 min
(total run time per sample was 50 min). Ionized peptides were ana-
lyzed in the mass spectrometer (0–106 m/z, global and Msx) using
the ‘‘triple play’’ mode, consisting initially of a survey (MS) spec-
trum from which the three most abundant ions were determined
(threshold = 200–500 TIC). Collision energy was set at 35% for
30 min. The charge state of each ion was then assigned from the
C13 isotope envelope ‘‘zoom scan’’ and ﬁnally subjected to a third
MS/MS scan. The LTQ was tuned using a 500 fmol/lL solution of
gluﬁbrinopeptide (m/z 785.5, [M = 2H]2+) and calibrated according
to the manufacturer’s instructions. The resulting MS/MS spectra
(data ﬁles) were merged into an mgf ﬁle, which was submitted
to Mascot searching. Mascot searching was carried out on a local
Mascot server against gene annotations from ToxoDB version 7.2
(http://toxodb.org/toxo/). MS/MS ion search was used to search
the data output from the LTQ. Database search parameters in-
cluded: ﬁxed carbamidomethyl modiﬁcation of cysteine residues;
variable oxidation of methionine; a peptide tolerance of ±1.5 Da;
MS/MS tolerance ±0.8 Da; +1, +2, +3 peptide charge state; and a
single missed trypsin cleavage. Instrument was set as ESI-TRAP.2.9. GO analysis
GO descriptions of the proteins identiﬁed were retrieved from
ToxoDB 7.2. The remaining proteins were mapped onto UniProt
DB using GI numbers to obtain GO descriptions.
Table 1
Identiﬁcation by LC–MS/MS of T. gondii differentially expressed proteins from Type I strains: resistant strain (TgA 103001) versus sensitive strain (RH).
Spot
No.
Accession No.a Protein name MW/pIb Scorec Sequence
coverage
Identiﬁed
peptidesd
Average
ratiose
Carbohydrate metabolism
1921 TGME49_056760 Pyruvate kinase 58120/
6.36
632 16 17 1.74
2859 TGME49_032350 Lactate dehydrogenase 36095/
6.29
99 3 2 1.91
2060 TGME49_068850 Enolase 2 52765/
6.84
266 10 6 1.68
2051 TGME49_068850 Enolase 2 52765/
6.84
293 7 5 2.27
Protein folding
1484 TGME49_073760 Heat shock protein 70, putative 73291/
4.82
366 10 11 1.41
Host cell interaction
3076 TGME49_043730 p36 protein, ROP9 37986/
8.37
380 13 11 1.31
Others/unknown functions
1967 TGME49 061950 ATP synthase beta chain, putative 60107/
6.86
382 6 6 1.74
1860 TGME49_101440 CAM kinase, CDPK family, TgCDPK1 65893/
6.39
253 4 4 2.55
1244 TGME49_043960 Ras-GTPase-activating protein binding protein,
putative
84372/
9.43
122 2 4 1.78
1781 TGME49_033110 Inosine-5’-monophosphate dehydrogenase, putative 59409/
7.07
323 15 12 1.51
1614 TGME49 031630 Membrane skeletal protein IMC1, putative 50596/
5.85
87 1 2 1.81
1494 TGME49_016970 Hypothetical protein, conserved 69027/
5.39
434 13 13 1.3
2240 TGME49_009600 Hypothetical protein 50398/
4.92
155 6 4 1.77
2214 TGME49_013030 Hypothetical protein 35249/
4.31
161 8 4 1.37
a Gene identiﬁcation in ToxoDB.
b Theoretical molecular weight and pI.
c MASCOT score.
d Number of identiﬁed peptides.
e Average volume ratio of the spots (resistant versus sensitive) with p < 0.05, Student’s t-test.
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Proteins of T. gondii tachyzoites were extracted with RIPA buf-
fer. Proteins (10 lg) were separated on 12.5% SDS–PAGE, and
transferred to nitrocellulose membrane. The membranes were
blocked overnight at 4 C, incubated 1 h with the primary antibody
against speciﬁc proteins diluted at 1/5000 for ENO2 and IMC1 (gift
from Dr. S. Tomavo), 1/2000 for GRA7 (Abbott), 1/1000 for ROP2
and MIC2 (gift from Dr. J.F. Dubremetz) and for SAG-1 (GII9, Argene
Biosoft). Peroxydase-conjugated anti-rabbit or anti-mouse second-
ary antibodies were used (Biorad, 1/3000). SAG-1 was used as po-
sitive control in all strains used. All analysis were performed in
triplicate, values are expressed as mean ± SD.2.11. RNA extraction and qRT-PCR analysis
The Toxoplasma stage preparation was controlled through the
stage-speciﬁc markers sag1, bag1 and eno1 by qRT-PCR (Supple-
mental data 1). These genes were chosen as bradyzoite markers
(bag1 (Bohne et al., 1995) and eno1 (Holmes et al., 2010)) and tach-
yzoite markers (sag1 (Burg et al., 1988)). Total RNAs of each strain
were extracted using the RNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. One microgram of total RNA was
reverse transcribed to cDNA using the iScript Transcription Super-
mix (Bio-Rad, USA) according to the manufacturer’s instructions.
The qRT-PCR was performed using the IQ™ SYBER Supermix kit(Bio-Rad) with an iCycler™ iQ real-time PCR Detection system
(Bio-Rad). PCR primers (Invitrogen™ life technologies, France)
were designed using ProbeFinder Version: 2.45 (Roche Applied Sci-
ence) to speciﬁcally amplify sequences of rop2: 50-TCA CGC TTC
AGC TCA TAA GG-30 (forward) and 50-GAA AAT CGG CAT GCA
CAA G-30 (reverse); mic2: 50-GGG GTA TGT GCT GTT GAC G-30 (for-
ward) and 50-GTG GCA TTT CCG CAA GAC-30 (reverse); eno2: 50-
GCG ACC AGA AGG GTA TTG AC-30 (forward) and 50-AGC CCC
ACT CGT TCT TAG TTC-30 (reverse); imc1: 50-GAA CGC TTG CTC
AAG GAG A-30 (forward) and 50-TTG AAG ACC TGC TCC ACC TT-30
(reverse); and toxoplasma b-tubulin: 50-TCT TCC GCC CTG ACA
ACT TC-30 (forward) and 50-CCG CAC CCT CAG TGT AGT GA-30 (re-
verse). The PCR proﬁle was 3.5 min at 95 C, 40 (15 s at 95 C,
1 min at 60 C) and 1 min at 80 C.2.12. Statistical analysis
The mRNA levels of rop2, mic2, eno2 and imc1 genes were nor-
malized to housekeeping toxoplasma b-tubulin gene using the 2DCt
method. All real time qRT-PCR experiments were performed in
duplicate; values are expressed as a median ± interquartile spaces
(IQs) of Ct values, and analyzed using a non-parametric exact Wil-
coxon–Mann–Whitney test (StatXact software, CytelSudio7). The
statistically signiﬁcant differences level was deﬁned as ⁄p < 0.05
and ⁄⁄p < 0.01.
Table 2
Identiﬁcation by LC–MS/MS of T. gondii differentially expressed proteins from Type II strains: resistant strain (TgH 32006) versus sensitive strain (ME-49).
Spot No. Accession No.a Protein name MW/pIb Scorec Sequence coverage (%) Identiﬁed peptidesd Average ratiose
Carbohydrate metabolism
1630 TGME49_089690 Glyceraldehyde-3-phosphate dehydrogenase 36629/7.25 87 13 3 3.86
1523 TGME49_089690 Glyceraldehyde-3-phosphate dehydrogenase 36629/7.25 181 13 3 1.59
Host cell interaction
1609 TGME49 015780 Rhoptry kinase family protein ROP2A 66748/6.91 75 4 3 2.12
698 TGME49_001780 Microneme protein 2 77584/4.41 74 4 4 1.62
2148 TGME49_027620 28 kDa antigen (GRA2) 19805/10 64 18 11 1.82
2056 TGME49_014080 Toxoﬁlin 26789/
10.13
481 23 16 1.43
2077 TGME49_014080 Toxoﬁlin 26789/
10.13
167 12 4 1.37
1645 TGME49_070320 Protein Phosphatase 2C, putative 58675/4.72 122 2 2 1.46
Translation
2533 TGME49 051810 Translation initiation factor eIF-5A, putative 17468/5.03 113 13 3 1.49
1043 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 628 26 12 1.75
1354 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 249 12 6 2.59
1069 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 191 7 3 1.63
1362 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 67 7 3 2.29
1448 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 311 13 3 1.47
1272 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 107 10 5 1.98
1593 TGME49_086420 Elongation factor 1 alpha, putative 49006/9.39 111 13 7 1.55
1848 TGME49_062620 Gbp1p protein, putative 31761/9.29 202 9 6 1.45
1505 TGME49_110640 Uridine phosphorylase, putative 33043/7.12 83 6 2 1.58
a Gene identiﬁcation in ToxoDB.
b Theoretical molecular weight and pI.
c MASCOT score.
d Number of identiﬁed peptides.
e Average volume ratio of the spots (resistant versus sensitive) with p < 0.05, Student’s t-test.
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3.1. Identiﬁcation of differentially expressed proteins
For this study, we used a 2D-DIGE approach to identify proteins
associated in natural resistance mechanisms to sulfadiazine (Sup-
plemental data 2). Protein abundance was compared between sul-
fadiazine sensitive and resistant strains from T. gondii with same
genotype: RH versus TgA 103001 (Type I), ME-49 versus TgH
32006 (Type II) and ME-49 versus TgH 32045 (Type II variant). Pro-
tein spots which appeared with at least a 1.3-fold change
(p 6 0.05) between resistant and sensitive strains were used for
analysis. Fourteen protein spots were identiﬁed in the Type I
strain: only one of them, identiﬁed as a hypothetical protein, in-
creased in the resistant strain TgA 103001 and 13 increased in
the sensitive RH strain (Table 1). Eighteen protein spots were in
different abundance in Type II strains: 17 of them were over-ex-
pressed in the resistant strain TgH 32006 and one in the sensitive
strain ME-49 (Table 2). Fifteen protein spots were identiﬁed in the
Type II variant strain: ﬁve of them over-expressed in TgH 32045
and 10 were over-expressed in the sensitive ME-49 strain (Table 3).
However, some proteins were detected in more than one gel spot,
most likely representing isoenzymes, proteins with post-transla-
tional modiﬁcation or protein degradation. When the redundancy
was removed, 13 unique protein identiﬁcations were acquired
from the 14 spots identiﬁed from the genotype I strains (RH and
TgA 103001); 10 unique protein identiﬁcations acquired from the
18 spots identiﬁed from the Type II strains (ME-49 and TgH
32006); and 12 unique protein identiﬁcations acquired from the
15 spots identiﬁed from the Type II variant strain (ME-49 and
TgH 32045). In total, 31 proteins, including four hypothetical pro-
teins, were identiﬁed from the three experiments, 44% were over-
expressed in resistant strains and 56% were over-expressed in sen-
sitive strains. Interestingly, GRA7 was identiﬁed in two gel spots
and showed contradictory expression changes in these gel spots:
one appearing more abundant in TgH 32045 and the other one in
ME-49.3.2. Gene ontology analysis of the identiﬁed proteins
The 27 identiﬁed proteins (excluding hypothetical proteins)
were annotated by GO analysis. Modulated proteins were classiﬁed
into ﬁve functional groups (Fig. 1) such as carbohydrate metabo-
lism (four proteins: pyruvate kinase, lactate dehydrogenase,
ENO2 and G3PDH), host cell interaction (nine proteins: ROP9,
ROP2A, MIC1, MIC2, GRA2, GRA7, Toxoﬁlin, PP2C and SRS29C),
translation (two proteins: eIF-5A and EF1-a), protein folding (three
proteins: small Hsp20, Hsp70 and Hsp90) and nine proteins as the
group others/unknown functions. None of the proteins identiﬁed
were found in all three of the experiments but four proteins were
common to two of the strain comparisons. For example, ENO2 and
IMC1 are under-expressed in the resistant strains TgA 103001
(Type I) and TgH 32045 (Type II variant) in comparison to the sen-
sitive strains RH andME-49. MIC2 is under-expressed in the Type II
resistant strains, TgH 32006 and TgH 32045, in comparison to the
sensitive strain ME-49 while ROP2A is over-expressed in TgH
32006 and TgH 32045 than in ME-49.
3.3. Conﬁrmation of protein regulation by Western blotting
We conﬁrmed by Western blotting proteins regulation of sev-
eral proteins identiﬁed in DIGE: ENO2, IMC1, ROP2, MIC2 and
GRA7 in the different strains studied. We also analyzed these pro-
teins regulation in two others sensitive strains of genotype I (ENT)
and genotype II (PRU) (Fig. 2). As shown in DIGE, ENO2 and IMC1
were up-regulated in the two sensitive strains RH and ME-49 but
also in the two others sensitive strains ENT and PRU in comparison
to the three resistant strains. ROP2 was shown over-expressed in
the two genotype II resistant strains TgH 32006 and TgH 32045
in DIGE experiments. We observed, in Western blot, the same re-
sults as DIGE for the active form of ROP2 for TgH 32006 only.
The precursor form showed a down-regulation. However the mass
spectrometry is not able to determine the precursor or the active
form of the protein identiﬁed. For MIC2 we observed the same re-
sults as DIGE for the active form of the protein. Results obtained
Table 3
Identiﬁcation by LC–MS/MS of T. gondii differentially expressed proteins from Type II variant resistant strain (TgH 32045) versus Type II sensitive strain (ME-49).
Spot
No.
Accession No.a Protein name MW/pIb Scorec Sequence
coverage (%)
Identiﬁed
peptidesd
Average
ratiose
Carbohydrate metabolism
793 TGME49 068850 Enolase 2 52765/
6.84
95 4 3 1.44
Host cell interaction
1684 TGME49 003310 Dense granule protein 7 25919/
5.06
88 4 2 1.42
2138 TGME49 003310 Dense granule protein 7 25919/
5.06
78 11 4 1.59
634 TGME49_091890 Microneme protein 1 48629/
4.94
53 7 2 2.22
721 TGME49 091890 Microneme protein 1 48629/
4.94
69 9 5 1.42
622 TGME49 091890 Microneme protein 1 48629/
4.94
159 9 7 1.49
560 TGME49_001780 Microneme protein 2 77584/
4.41
81 2 2 2.03
1760 TGVEG 030040 Rhoptry kinase family protein ROP2A 66748/
6.91
68 2 2 1.51
832 TGME49_033480 SRS29C
(=SRS2, p35)
39120/
7.3
72 3 6 2.36
Protein folding
2200 TGME49_032940 Small heat shock protein 20, putative 21035/
5.36
88 14 5 1.31
839 TGME49 044560 Heat shock protein 90, putative 96824/
4.7
65 6 4 2.96
Others/unknown functions
1318 TGME49 031630 Membrane skeletal protein IMC1, putative 50172/
5.85
302 5 6 2.04
2330 TGME49 014790 Mitochondrial glycoprotein domain
containing protein
31444/
4.39
52 3 2 1.42
2366 TGME49_077240 Nucleoside triphosphatase I 69157/
6.21
151 10 9 2.23
2317 TGME49_058870 Hypothetical protein 61948/
4.65
125 3 2 1.32
a Gene identiﬁcation in ToxoDB.
b Theoretical molecular weight and pI.
c MASCOT score.
d Number of identiﬁed peptides.
e Average volume ratio of the spots (resistant versus sensitive) with p < 0.05, Student’s t-test.
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which presents genetic recombination and deletion for some
genes, e.g. gra7 (GenBank Accession No. DQ465955). So we can
hypothesize that antibodies used cannot recognize the protein epi-
tope. GRA7 protein showed an up-regulation in the Type II sensi-
tive strains in comparison to the Type II resistant strains. The
two sensitive strains of same genotype have shown the same pro-
tein regulation for the protein studied.
3.4. Conﬁrmation of differentially expressed proteins at the mRNA level
In order to verify the Toxoplasma stage preparation, gene
expression levels of sag1 (tachyzoites markers) bag1 and eno1
(bradyzoites markers) were analyzed by qRT-PCR. Our results
showed that only sag1 gene expression was highly expressed for
all strains studied (Supplemental data 1), this conﬁrms the pres-
ence of only tachyzoites in our samples. Then, to conﬁrm the differ-
ential expression of proteins common to two of the strain
comparisons, gene expression levels of rop2, mic2, eno2 and imc1
were determined by qRT-PCR (Fig. 3). For the Type II strains, the re-
sults showed that the transcription levels of rop2 (signiﬁcant at
p < 0.01) (Fig. 3A) and eno2 (signiﬁcant at p < 0.05) (Fig. 3C) were
consistent with the protein levels identiﬁed by DIGE. For the Type
I strains, ROP2 and MIC2 proteins were not identiﬁed as differen-
tially expressed by DIGE but their gene expression levels were sig-
niﬁcantly (p < 0.01) more abundant in the resistant strain TgA103301 (Fig. 3A and B); eno2 gene showed different expression
patterns between the transcription and protein expression levels
(Fig. 3C): ENO2 protein was more expressed in the sensitive strain
RH while eno2 expression level is signiﬁcantly reduced in the RH
strain (p < 0.01). No modulation of imc1 gene expression was ob-
served between sensitive and resistant strain whichever the geno-
type (Fig. 3D).
4. Discussion
There is increasing evidence for the emergence of strains of T.
gondii that are resistant to treatment with sulfonamide and/or
pyrimethamine-based compounds. In collaboration with Meneceur
et al. (2008), we have recently isolated three strains of T. gondii
resistant to sulfadiazine. As there is no apparent correlation with
strain genotype or to mutations in drug target genes, in this study
we used a proteomics approach to investigate the basis of drug
resistance in these resistant strains.
We identiﬁed 31 unique proteins, including four hypothetical
proteins, differentially expressed between resistant and sensitive
strains to sulfadiazine. Some of the proteins which exhibited mod-
ulation between resistant and sensitive parasites were associated
with carbohydrate metabolism (G3PDH, ENO2, lactate dehydroge-
nase and pyruvate kinase). These four proteins are involved in the
glycolysis mechanism that plays important roles in stage conver-
sion in Toxoplasma (Tomavo, 2001) and in the closely related
TgA 103001/RH
(Type I) TgH 32045/ME-49
(Type II variant)
TgH 32006/ME-49
(Type II)
p36 protein (ROP9)
Lactate dehydrogenase
ENO 2
ATP synthase beta  chain
Pyruvate kinase
TgCDPK1
Inosine-5’-monophosphate dehydrogenase IMC1
Hsp70
Ras-GTPase-activating protein binding protein
MIC 1
MIC 2
SRS29C (=SRS2, p35)
Hsp90
Small Hsp20
GRA7
ROP2A
Mitochondrial glycoprotein
domain containing protein
Nucleoside triphosphatase I
EF1-α
G3PDH
Uridine phosphorylase
Toxofilin
eIF-5A
PP2C
Gbp1p
28 kDa antigen (GRA2)Carbohydrate metabolism
Host cell interaction
Protein folding
Translation
Others/Unknown functions
Fig. 1. View of protein expression sets identiﬁed as differentially regulated in three comparative strains comparison (without hypothetical proteins). Modulated proteins are
shown for each resistant isolate compared to either RH or ME-49 sensitive parasites. Protein function is indicated by colored boxes. Intersections show protein changes
identiﬁed which were common to each resistant isolate. Proteins over-expressed in resistant strains (TgA 103001, TgH 32045 and TgH 32006) are written in bold. Proteins
under-expressed in resistant strains are written in italics. Proteins identiﬁed in multiple gel spots and showing contradictory expression changes in different gel spots are
underlined.
C. Doliwa et al. / International Journal for Parasitology: Drugs and Drug Resistance 3 (2013) 35–44 41protozoan parasite Neospora caninum (Marugán-Hernández et al.,
2010). Here, the purity of Toxoplasma stage preparation was con-
trolled through the stage-speciﬁc markers SAG1, BAG1 and ENO1
(Supplemental data 1). Moreover, several proteins identiﬁed in this
study were previously found as markers of the tachyzoite stage:
p36 protein (ROP9) (Reichmann et al., 2002) and ENO2 (Tomavo,
2001) exclusively expressed in tachyzoites.
Among the differentially expressed proteins, a notable contribu-
tion of ENO2 has been reported in methotrexate resistance, an
antifolate drug used in the treatment of cancer and autoimmune
diseases (Selga et al., 2008). Kumar et al. (2010), in Leishmanaia
donovani, have shown the over expression of ENO2 in antimony de-
rived resistant strains (sodium antimony gluconate, an anti-
leishmanial drug). In this study, we found that ENO2 was over-
expressed in the two sensitive strains which could show a differ-
ence in pathways of the drug resistance mechanisms between
these parasites. It has been proposed that differential expression
of enolase in protozoan parasites may serve as a strategy for these
parasites to adapt to different environmental conditions (Kibe
et al., 2005).
In the present work, three heat shock proteins were identiﬁed
to be differentially expressed in resistant and sensitive strains:
small Hsp20, Hsp70 and Hsp90. HSPs are a family of proteins in-
duced in many disease processes. In protozoan systems, a link be-
tween HSP and development and intracellular survival has been
established (Shonhai, 2010). Hsp70 and Hsp90 were found more
expressed in the sensitive strains; this could be explained by the
higher necessity of the sensitive strains to facilitate the protein
folding.Moreover, we identiﬁed many proteins with differential expres-
sion which were associated with host cell interaction. In T. gondii,
MIC proteins, including MIC1 and MIC2 identiﬁed in this study,
are implicated in cellular processes including gliding motility, ac-
tive cell invasion and migration (Carruthers and Tomley, 2008).
Toxoﬁlin is an actin binding protein which is associated with
PP2C and secreted into host cells during invasion (Jan et al.,
2007), although the main role of toxoﬁlin remains unclear (Lodoen
et al., 2010). T. gondii dense granule proteins participate in the
modiﬁcation of the parasitophorous vacuole (PV), which provides
an unusual and highly specialized environment for parasite growth
and development (Smith, 1995). Previous studies have shown that
GRA2, a dense granule protein of T. gondii plays a role in protein
trafﬁcking to the dense granules, secretion into the vacuole, asso-
ciation with vacuolar membranes, induction of the membranous
nanotubular network formation and organization of the parasites
within the vacuole (Travier et al., 2008) and in this study the abun-
dance of 28 kDa antigen (GRA2) was higher in the resistant strain
TgH 32006 compared to the sensitive strain. Another dense granule
protein, GRA7, was identiﬁed from two separate gel spots with
ﬂuctuating expression in the comparison between TgH 32045
and ME-49. This would suggest that post-translational modiﬁca-
tion or processing generated the modulation observed. This modu-
lation of GRA7 alongside an increase in NTPase I within the TgH
32045 strain is interesting as both of these proteins are known to
play a role in the virulence of T. gondii tachyzoites (Nischik et al.,
2001; Choi et al., 2010). Our results indicated that SRS29C protein
(=SRS2, p35), a SAG-1 Related Sequence member, was over-
expressed in the sensitive strain ME-49. SRS2 protein was also
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Fig. 2. Analysis by Western blot of ENO2, IMC1, ROP2, MIC2 and GRA7 modulation in T. gondii sulfadiazine sensitive (RH and ENT (Type I), ME-49 and PRU (Type II)) and
resistant strains (TgA103001 (Type I), TgH 32006(Type II) and TgH 32045(Type II variant)) (A) and corresponding densitometry analysis (B). SAG-1 was used as positive
control in all strains used. All Western blot analysis were performed in triplicate, values are expressed as mean ± SD.
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the highly virulent strain RH but the correlation with virulence is
unknown (Manger et al., 1998).
In toxoplasmosis treatment, sulfonamides inhibit parasite repli-
cation by interfering in folate synthesis and also in purine biosyn-
thesis. Indeed, folic acid is an important cofactor in purine
biosynthesises. IMP dehydrogenase (IMPDH) is an enzyme which
catalyzes the NAD-dependent conversion of IMP to XMP in the de
novo purine nucleotide synthetic pathway. IMPDH was shown to
be increased signiﬁcantly in cancer cells and therefore considered
to be a sensitive target for cancer chemotherapy (Franchetti and
Grifantini, 1999), but also for T. gondii (Sullivan et al., 2005), and
C. parvum (Sharling et al., 2010).
In this study we used a 2-DE approach to analyze proteome
changes. However, visualization of membrane proteins in 2-DEgels is poor which limits our observation of proteins such as ABC
transporters, or hydrophobic proteins like the ROP2-8 family
(Ajioka and Soldati, 2007) due to their poor solubility (Rabilloud
et al., 2010). Moreover, the solubilization protocol used in this
study was not adapted for membrane proteins which require a
carefully balanced hydrophilic and lipophilic environment
(Rabilloud, 2009).
Nevertheless, clear differential protein expression was observed
in resistant strains and by comparing results between themselves,
several protein changes were common to more than one isolate.
ROP2A and MIC2 were found to be modulated in both TgH
32006/ME-49 and TgH 32045/ME-49; ENO2 and IMC1 were found
regulated in both TgA 103001/RH and TgH 32045/ME-49. The com-
parison of the protein expression with gene expression reveals
some interesting discrepancies. Gene expression levels of rop2
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Fig. 3. Relative expression of rop2, mic2, eno2 and imc1 genes by real-time qRT-PCR
analysis. The mRNA levels of rop2, mic2, eno2 and imc1 genes were normalized to
housekeeping toxoplasma b-tubulin gene. Results are representative of six indepen-
dent experiments and presented as median ± interquartile space (IQs) of relative
variation of Ct values between RH/TgA 103001strains, ME-49/TgH 32006 strains
and ME-49/TgH32045 strains. ⁄p < 0.05 and ⁄⁄p < 0.01 represent signiﬁcant differ-
ence between strains (non-parametric exact Wilcoxon–Mann–Whitney test). ND:
not determined.
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DIGE) for Type II strain. No modulation of imc1 gene expressionwas observed between sensitive and resistant strain whichever
the genotype. On the other hand, gene expression of eno2was con-
tradictory with protein expression in Type I strains, this may be
due to post-translational modiﬁcations or protein degradation.
Moreover eno2 and mic2 expression levels were increased in the
resistant Type I strain but not in the two resistant Type II strains,
indicating that resistant mechanisms could be different among
the strain genotype. In order to examine the intimate and complex
relationship between transcription and translation, Wastling et al.
(2009) reviewed advances in proteomic and transcriptomic in the
Apicomplexa and many discrepancies between these types of data
were highlighted. Indeed, numerous studies showed the presence
of proteomic evidence and little or no mRNA expression evidence
(detected by ESTs or microarrays) in the same analysis and vice
versa. It is known that certain types of proteins may be under-rep-
resented in proteomic analysis due to their physicochemical com-
position, low levels of expression or high rates of turn-over and
degradation.
One important point, of this study, is the possibility of variation
in proteins levels due to strain to strain variation between para-
sites. Indeed in this study we compared proteomes of sensitive
and resistant T. gondii strains from same genotype in order to iden-
tify sulfadiazine resistance mechanisms, and we found several pro-
teins regulated in different abundance. However, no comparison by
DIGE was presented here between two sulfadiazine sensitive
strains of same genotype. Nevertheless, we conﬁrmed by Western
blotting proteins regulation of several interesting proteins identi-
ﬁed in DIGE (ENO2, IMC1, ROP2, MIC2 and GRA7) in the different
strains studied. We also analyzed these proteins regulation in
two others sensitive strains of genotype I (ENT) and genotype II
(PRU), and we found the same results as in DIGE. However, we can-
not exclude that differentially expressed proteins identiﬁed in our
study may be due to strain to strain variation and not only to sul-
fadiazine resistance. Further proteomic studies using strains of
T. gondii where sulfadiazine resistance has been induced by
in vitro methods are also warranted.
In conclusion, we have identiﬁed 31 proteins which are differ-
entially modulated between sulfadiazine resistant and sensitive
strains of T. gondii according to their genotype. These proteins
were predicted to be involved in several different mechanisms
such as carbohydrate metabolism, host cell interaction and
protein translation. Although none of them allow us to identify
directly resistance mechanisms to sulfadiazine at this stage,
several of these proteins represent encouraging potential targets
to be followed-up.Acknowledgments
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